α-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma

L. T. Chen, T. W. Liu, Y. Chao, H. S. Shiah, J. Y. Chang, S. H. Juang, S. C. Chen, T. R. Chuang, Y. H. Chin, J. Whang-Peng

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: Radiographic measurements do not always reflect the biological response of hepatocellular carcinoma to drug therapy. Aims: To evaluate the clinical implications of tumour marker (α-fetoprotein) response in advanced hepatocellular carcinoma patients with thalidomide treatment. Patients and methods: Forty-two advanced hepatocellular carcinoma patients with baseline α-fetoprotein levels above 200 ng/mL and thalidomide therapy were included. Serum α-fetoprotein levels were measured every 4 weeks, α-fetoprotein response was defined as a 50% or greater reduction of α-fetoprotein levels for 4 or more weeks during treatment. Radiographic response was assessed by World Health Organization criteria; survivals were estimated by Kaplan-Meier method and prognostic factors were assessed by Cox's proportional hazard model. Results: With intention-to-treat analysis, radiographic response and α-fetoprotein response were obtained in 7% (three of 42, 95% confidence interval: 0-15) and 24% (10 of 42, 95% CI: 10-38) of patients, respectively. All radiographic response was observed in α-fetoprotein responders. Multivariate analyses showed α-fetoprotein response was independent prognostic factor for both progression-free survival (relative risk = 0.394, 95% CI: 0.189-0.820, P = 0.013) and overall survival (relative risk = 0.241, 95% CI: 0.096-0.606, P = 0.003), whereas radiographic response was not. Conclusion: α-fetoprotein response can more accurately reflect the biological response of advanced hepatocellular carcinoma to thalidomide therapy than radiographic response.

Original languageEnglish
Pages (from-to)217-226
Number of pages10
JournalAlimentary Pharmacology and Therapeutics
Volume22
Issue number3
DOIs
Publication statusPublished - Aug 1 2005
Externally publishedYes

Fingerprint

Fetal Proteins
Thalidomide
Hepatocellular Carcinoma
Survival
Intention to Treat Analysis
Therapeutics
Tumor Biomarkers
Proportional Hazards Models
Disease-Free Survival
Multivariate Analysis
Confidence Intervals
Drug Therapy

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

α-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma. / Chen, L. T.; Liu, T. W.; Chao, Y.; Shiah, H. S.; Chang, J. Y.; Juang, S. H.; Chen, S. C.; Chuang, T. R.; Chin, Y. H.; Whang-Peng, J.

In: Alimentary Pharmacology and Therapeutics, Vol. 22, No. 3, 01.08.2005, p. 217-226.

Research output: Contribution to journalArticle

Chen, L. T. ; Liu, T. W. ; Chao, Y. ; Shiah, H. S. ; Chang, J. Y. ; Juang, S. H. ; Chen, S. C. ; Chuang, T. R. ; Chin, Y. H. ; Whang-Peng, J. / α-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma. In: Alimentary Pharmacology and Therapeutics. 2005 ; Vol. 22, No. 3. pp. 217-226.
@article{f8ce5162111d43ec9aed1ae93ee1b136,
title = "α-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma",
abstract = "Background: Radiographic measurements do not always reflect the biological response of hepatocellular carcinoma to drug therapy. Aims: To evaluate the clinical implications of tumour marker (α-fetoprotein) response in advanced hepatocellular carcinoma patients with thalidomide treatment. Patients and methods: Forty-two advanced hepatocellular carcinoma patients with baseline α-fetoprotein levels above 200 ng/mL and thalidomide therapy were included. Serum α-fetoprotein levels were measured every 4 weeks, α-fetoprotein response was defined as a 50{\%} or greater reduction of α-fetoprotein levels for 4 or more weeks during treatment. Radiographic response was assessed by World Health Organization criteria; survivals were estimated by Kaplan-Meier method and prognostic factors were assessed by Cox's proportional hazard model. Results: With intention-to-treat analysis, radiographic response and α-fetoprotein response were obtained in 7{\%} (three of 42, 95{\%} confidence interval: 0-15) and 24{\%} (10 of 42, 95{\%} CI: 10-38) of patients, respectively. All radiographic response was observed in α-fetoprotein responders. Multivariate analyses showed α-fetoprotein response was independent prognostic factor for both progression-free survival (relative risk = 0.394, 95{\%} CI: 0.189-0.820, P = 0.013) and overall survival (relative risk = 0.241, 95{\%} CI: 0.096-0.606, P = 0.003), whereas radiographic response was not. Conclusion: α-fetoprotein response can more accurately reflect the biological response of advanced hepatocellular carcinoma to thalidomide therapy than radiographic response.",
author = "Chen, {L. T.} and Liu, {T. W.} and Y. Chao and Shiah, {H. S.} and Chang, {J. Y.} and Juang, {S. H.} and Chen, {S. C.} and Chuang, {T. R.} and Chin, {Y. H.} and J. Whang-Peng",
year = "2005",
month = "8",
day = "1",
doi = "10.1111/j.1365-2036.2005.02547.x",
language = "English",
volume = "22",
pages = "217--226",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - α-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma

AU - Chen, L. T.

AU - Liu, T. W.

AU - Chao, Y.

AU - Shiah, H. S.

AU - Chang, J. Y.

AU - Juang, S. H.

AU - Chen, S. C.

AU - Chuang, T. R.

AU - Chin, Y. H.

AU - Whang-Peng, J.

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Background: Radiographic measurements do not always reflect the biological response of hepatocellular carcinoma to drug therapy. Aims: To evaluate the clinical implications of tumour marker (α-fetoprotein) response in advanced hepatocellular carcinoma patients with thalidomide treatment. Patients and methods: Forty-two advanced hepatocellular carcinoma patients with baseline α-fetoprotein levels above 200 ng/mL and thalidomide therapy were included. Serum α-fetoprotein levels were measured every 4 weeks, α-fetoprotein response was defined as a 50% or greater reduction of α-fetoprotein levels for 4 or more weeks during treatment. Radiographic response was assessed by World Health Organization criteria; survivals were estimated by Kaplan-Meier method and prognostic factors were assessed by Cox's proportional hazard model. Results: With intention-to-treat analysis, radiographic response and α-fetoprotein response were obtained in 7% (three of 42, 95% confidence interval: 0-15) and 24% (10 of 42, 95% CI: 10-38) of patients, respectively. All radiographic response was observed in α-fetoprotein responders. Multivariate analyses showed α-fetoprotein response was independent prognostic factor for both progression-free survival (relative risk = 0.394, 95% CI: 0.189-0.820, P = 0.013) and overall survival (relative risk = 0.241, 95% CI: 0.096-0.606, P = 0.003), whereas radiographic response was not. Conclusion: α-fetoprotein response can more accurately reflect the biological response of advanced hepatocellular carcinoma to thalidomide therapy than radiographic response.

AB - Background: Radiographic measurements do not always reflect the biological response of hepatocellular carcinoma to drug therapy. Aims: To evaluate the clinical implications of tumour marker (α-fetoprotein) response in advanced hepatocellular carcinoma patients with thalidomide treatment. Patients and methods: Forty-two advanced hepatocellular carcinoma patients with baseline α-fetoprotein levels above 200 ng/mL and thalidomide therapy were included. Serum α-fetoprotein levels were measured every 4 weeks, α-fetoprotein response was defined as a 50% or greater reduction of α-fetoprotein levels for 4 or more weeks during treatment. Radiographic response was assessed by World Health Organization criteria; survivals were estimated by Kaplan-Meier method and prognostic factors were assessed by Cox's proportional hazard model. Results: With intention-to-treat analysis, radiographic response and α-fetoprotein response were obtained in 7% (three of 42, 95% confidence interval: 0-15) and 24% (10 of 42, 95% CI: 10-38) of patients, respectively. All radiographic response was observed in α-fetoprotein responders. Multivariate analyses showed α-fetoprotein response was independent prognostic factor for both progression-free survival (relative risk = 0.394, 95% CI: 0.189-0.820, P = 0.013) and overall survival (relative risk = 0.241, 95% CI: 0.096-0.606, P = 0.003), whereas radiographic response was not. Conclusion: α-fetoprotein response can more accurately reflect the biological response of advanced hepatocellular carcinoma to thalidomide therapy than radiographic response.

UR - http://www.scopus.com/inward/record.url?scp=23844534451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844534451&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2005.02547.x

DO - 10.1111/j.1365-2036.2005.02547.x

M3 - Article

VL - 22

SP - 217

EP - 226

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 3

ER -